Creating new workflows to improve discovery and development
Efforts focus on creation of new applications for high-resolution platform
FOSTER CITY, Calif.—AB Sciex has taken the wraps off a collaboration with the University of Geneva's Mass Spectrometry Centre to create new workflows and analytical strategies for improving drug discovery and development.
The collaboration is focused on developing specific applications for use with a groundbreaking platform that will be the life science industry's first mass spectrometry system to combine both qualitative and quantitative analysis at high resolution and high sensitivity with accurate mass. AB Sciex will launch the system later this year.
AB Sciex President Laura Lauman says the company is focused on bringing continuous innovation to the mass spectrometry market.
"The future launch of the world's first high-resolution, accurate-mass system with high-sensitivity qualitative and quantitative workflows will represent a game-changing technology platform that will have significant impact in the ways scientists conduct mass spectrometry-based experiments," she notes. "This new innovation, which is supported by strategies for metabolite identification developed in collaboration with the University of Geneva, will provide the pharmaceutical industry with a unique workflow solution to improve drug discovery and development."
Lauman notes that selecting the University of Geneva's Mass Spectrometry Centre for this partnership was an easy decision.
"The scientists at the University of Geneva's Mass Spectrometry Centre are among the world's leading life scientists for using mass spectrometry technologies for pharmaceutical application development," she says. "Their expertise complements the innovations that AB Sciex is developing."
According to AB Sciex, there are significant advantages to a mass spectrometry system that combines both qualitative and quantitative analysis in such a manner.
"The advantages include significantly improved data quality and faster answers that pharmaceutical companies would use to make decisions about drug discovery and development," the company said in a statement.
The AB Sciex platform also is expected to advance a number of mass spectrometry applications, such as metabolite identification for drug discovery and development; proteomics for protein and biomarker research; and general unknown screening of chemicals for food and environmental testing. The collaboration with the University of Geneva will help establish the step-by-step processes of analysis that will improve metabolism studies to generate the most complete data.
The University of Geneva's Mass Spectrometry Centre, whose scientists are among the world's leading experts in mass spectrometry-based pharmaceutical applications, is applying this innovative technology for metabolite identification. Metabolite identification is a critical application for studying the efficacy and safety of new chemical entities in the drug discovery and development pipeline, ranging from early drug discovery to clinical trials. By having the capabilities to simultaneously identify metabolites with high resolution accurate mass and quantify them with high sensitivity, the scientists in Geneva are assisting AB Sciex in developing advanced workflows and software applications that are expected to help accelerate the adoption of the new platform within the pharmaceutical industry.
"The new AB Sciex accurate-mass technology is among the most important developments in mass spectrometry technologies in years," says Dr. Gerard Hopfgartner, professor and scientist, University of Geneva's Mass Spectrometry Centre. "The ability to integrate qualitative and quantitative analysis within a single platform enables new and better ways to think about conducting experiments. By developing novel workflows to take advantage of the new platform, we will be able to better understand biological systems and improve the drug discovery process."
Company officials are quick to point out this isn't the first time these parties have come together in a collaborative effort.
"The University of Geneva's Mass Spectrometry Centre collaborated with the company almost a decade ago on the development of the highly successful QTRAP technology, which is an innovative technology that combined qualitative and quantitative analysis," according to the company. "Development of advanced workflows and software applications that can be deployed on the AB Sciex high-resolution, accurate-mass platform will be the measure of success for this collaboration."
The collaboration is focused on developing specific applications for use with a groundbreaking platform that will be the life science industry's first mass spectrometry system to combine both qualitative and quantitative analysis at high resolution and high sensitivity with accurate mass. AB Sciex will launch the system later this year.
AB Sciex President Laura Lauman says the company is focused on bringing continuous innovation to the mass spectrometry market.
"The future launch of the world's first high-resolution, accurate-mass system with high-sensitivity qualitative and quantitative workflows will represent a game-changing technology platform that will have significant impact in the ways scientists conduct mass spectrometry-based experiments," she notes. "This new innovation, which is supported by strategies for metabolite identification developed in collaboration with the University of Geneva, will provide the pharmaceutical industry with a unique workflow solution to improve drug discovery and development."
Lauman notes that selecting the University of Geneva's Mass Spectrometry Centre for this partnership was an easy decision.
"The scientists at the University of Geneva's Mass Spectrometry Centre are among the world's leading life scientists for using mass spectrometry technologies for pharmaceutical application development," she says. "Their expertise complements the innovations that AB Sciex is developing."
According to AB Sciex, there are significant advantages to a mass spectrometry system that combines both qualitative and quantitative analysis in such a manner.
"The advantages include significantly improved data quality and faster answers that pharmaceutical companies would use to make decisions about drug discovery and development," the company said in a statement.
The AB Sciex platform also is expected to advance a number of mass spectrometry applications, such as metabolite identification for drug discovery and development; proteomics for protein and biomarker research; and general unknown screening of chemicals for food and environmental testing. The collaboration with the University of Geneva will help establish the step-by-step processes of analysis that will improve metabolism studies to generate the most complete data.
The University of Geneva's Mass Spectrometry Centre, whose scientists are among the world's leading experts in mass spectrometry-based pharmaceutical applications, is applying this innovative technology for metabolite identification. Metabolite identification is a critical application for studying the efficacy and safety of new chemical entities in the drug discovery and development pipeline, ranging from early drug discovery to clinical trials. By having the capabilities to simultaneously identify metabolites with high resolution accurate mass and quantify them with high sensitivity, the scientists in Geneva are assisting AB Sciex in developing advanced workflows and software applications that are expected to help accelerate the adoption of the new platform within the pharmaceutical industry.
"The new AB Sciex accurate-mass technology is among the most important developments in mass spectrometry technologies in years," says Dr. Gerard Hopfgartner, professor and scientist, University of Geneva's Mass Spectrometry Centre. "The ability to integrate qualitative and quantitative analysis within a single platform enables new and better ways to think about conducting experiments. By developing novel workflows to take advantage of the new platform, we will be able to better understand biological systems and improve the drug discovery process."
Company officials are quick to point out this isn't the first time these parties have come together in a collaborative effort.
"The University of Geneva's Mass Spectrometry Centre collaborated with the company almost a decade ago on the development of the highly successful QTRAP technology, which is an innovative technology that combined qualitative and quantitative analysis," according to the company. "Development of advanced workflows and software applications that can be deployed on the AB Sciex high-resolution, accurate-mass platform will be the measure of success for this collaboration."
